vs
Side-by-side financial comparison of UNITED SECURITY BANCSHARES (UBFO) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $13.5M, roughly 1.0× UNITED SECURITY BANCSHARES). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 25.2%, a 50.5% gap on every dollar of revenue. UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $-2.1M).
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
UBFO vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.5M | $13.7M |
| Net Profit | $3.4M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 31.5% | -86.5% |
| Net Margin | 25.2% | 75.7% |
| Revenue YoY | 13.6% | — |
| Net Profit YoY | 36.8% | 179.1% |
| EPS (diluted) | $0.18 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.5M | $13.7M | ||
| Q3 25 | $14.0M | $19.1M | ||
| Q2 25 | $12.6M | $8.1M | ||
| Q1 25 | $13.7M | $2.9M | ||
| Q4 24 | $11.9M | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $12.8M | — |
| Q4 25 | $3.4M | $10.4M | ||
| Q3 25 | $4.0M | $-16.3M | ||
| Q2 25 | $2.2M | $-15.8M | ||
| Q1 25 | $2.7M | $-13.3M | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $3.8M | — | ||
| Q2 24 | $4.3M | — | ||
| Q1 24 | $4.2M | — |
| Q4 25 | 31.5% | -86.5% | ||
| Q3 25 | 40.3% | -10.1% | ||
| Q2 25 | 24.0% | -177.7% | ||
| Q1 25 | 27.5% | -472.7% | ||
| Q4 24 | 27.5% | — | ||
| Q3 24 | 37.1% | — | ||
| Q2 24 | 46.4% | — | ||
| Q1 24 | 45.9% | — |
| Q4 25 | 25.2% | 75.7% | ||
| Q3 25 | 28.7% | -85.4% | ||
| Q2 25 | 17.2% | -196.0% | ||
| Q1 25 | 19.6% | -452.7% | ||
| Q4 24 | 20.9% | — | ||
| Q3 24 | 27.7% | — | ||
| Q2 24 | 33.0% | — | ||
| Q1 24 | 32.6% | — |
| Q4 25 | $0.18 | $-3.74 | ||
| Q3 25 | $0.23 | $-0.11 | ||
| Q2 25 | $0.13 | $-0.16 | ||
| Q1 25 | $0.16 | $-0.18 | ||
| Q4 24 | $0.14 | — | ||
| Q3 24 | $0.22 | — | ||
| Q2 24 | $0.25 | — | ||
| Q1 24 | $0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $264.2M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.7M | $35.3M |
| Total Assets | $1.2B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $264.2M | $137.5M | ||
| Q3 25 | $211.1M | $103.8M | ||
| Q2 25 | $199.5M | $121.6M | ||
| Q1 25 | $198.4M | $89.1M | ||
| Q4 24 | $216.9M | — | ||
| Q3 24 | $216.8M | — | ||
| Q2 24 | $166.3M | — | ||
| Q1 24 | $168.6M | — |
| Q4 25 | $139.7M | $35.3M | ||
| Q3 25 | $137.4M | $-8.1M | ||
| Q2 25 | $134.3M | $7.1M | ||
| Q1 25 | $132.9M | $10.7M | ||
| Q4 24 | $130.4M | — | ||
| Q3 24 | $132.9M | — | ||
| Q2 24 | $127.3M | — | ||
| Q1 24 | $124.2M | — |
| Q4 25 | $1.2B | $154.7M | ||
| Q3 25 | $1.2B | $133.7M | ||
| Q2 25 | $1.2B | $133.8M | ||
| Q1 25 | $1.2B | $103.7M | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.1M | $-2.0M |
| Free Cash FlowOCF − Capex | $19.8M | $-2.1M |
| FCF MarginFCF / Revenue | 146.0% | -15.3% |
| Capex IntensityCapex / Revenue | 16.8% | 0.7% |
| Cash ConversionOCF / Net Profit | 6.46× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $36.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $-2.0M | ||
| Q3 25 | $7.0M | $-17.5M | ||
| Q2 25 | $8.7M | $-14.5M | ||
| Q1 25 | $3.0M | $29.0M | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $5.4M | — | ||
| Q2 24 | $2.3M | — | ||
| Q1 24 | $7.4M | — |
| Q4 25 | $19.8M | $-2.1M | ||
| Q3 25 | $6.1M | — | ||
| Q2 25 | $8.1M | $-14.9M | ||
| Q1 25 | $2.9M | $29.0M | ||
| Q4 24 | $18.6M | — | ||
| Q3 24 | $5.3M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $7.0M | — |
| Q4 25 | 146.0% | -15.3% | ||
| Q3 25 | 43.7% | — | ||
| Q2 25 | 64.3% | -184.0% | ||
| Q1 25 | 21.2% | 988.3% | ||
| Q4 24 | 156.0% | — | ||
| Q3 24 | 38.1% | — | ||
| Q2 24 | 15.5% | — | ||
| Q1 24 | 54.8% | — |
| Q4 25 | 16.8% | 0.7% | ||
| Q3 25 | 6.0% | 0.0% | ||
| Q2 25 | 4.6% | 5.0% | ||
| Q1 25 | 0.9% | 0.8% | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | 6.46× | -0.19× | ||
| Q3 25 | 1.73× | — | ||
| Q2 25 | 4.01× | — | ||
| Q1 25 | 1.13× | — | ||
| Q4 24 | 7.87× | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 1.79× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
